Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ: REGN )

461.57 USD +12.19 (+2.71%)
Official Closing Price Updated: 7:58 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
From GlobeNewswire News Releases
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
From PR Newswire
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
From PR Newswire
EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
From PR Newswire
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with imdevimab) in non-hospitalized patients... 
From PR Newswire
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
From PR Newswire
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
From GlobeNewswire News Releases
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 
From PR Newswire
The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
From PR Newswire
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
From GlobeNewswire News Releases
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation
From PR Newswire
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
From PR Newswire
FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
From PR Newswire
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
From GlobeNewswire News Releases
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
From PR Newswire
New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
From PR Newswire
REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa
From PR Newswire
Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
From PR Newswire
Thinking about trading options or stock in Niu Technologies, Regeneron Pharmaceuticals, General Electric, Merck, or Axon Enterprise?
InvestorsObserver issues critical PriceWatch Alerts for NIU, REGN, GE, MRK, and AAXN. 
From PR Newswire
Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors 
From PR Newswire
Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
From PR Newswire
Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Friday, February 5, 2021, before the U.S.... 
From PR Newswire
Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
From PR Newswire
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
From PR Newswire
New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the... 
From PR Newswire
Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. The presentation is scheduled for 8:20... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.